The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

Jeffrey Small, Erik Washburn, Karmaine Millington, Junjia Zhu, Sheldon Holder

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Multiple therapies currently exist for renal cell carcinoma, however, most do not result in cure and the development of acquired resistance is the rule rather than the exception. CDK4/6 and PIM1 kinases are potential new therapeutic targets in RCC. Abemaciclib is a potent CDK4/6 and PIM1 kinase inhibitor, thus we evaluated the effects of abemaciclib on renal cell carcinoma. In vitro, abemaciclib causes decreased cellular viability, increased apoptosis, and alterations in autophagy in renal cell carcinoma cell lines. A pre-clinical mouse model of RCC shows abemaciclib in combination with sunitinib to cause dramatic reduction in tumor sizes without overt toxicity. Thus abemaciclib is active in renal cell carcinoma and should be evaluated in a clinical trial in combination with sunitinib. Additionally, CDK4/6 and PIM1 kinase appear to be viable clinical targets in renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)95116-95134
Number of pages19
JournalOncotarget
Volume8
Issue number56
DOIs
StatePublished - Jan 1 2017

Fingerprint

Renal Cell Carcinoma
Heterografts
Phosphotransferases
Neoplasms
Autophagy
sunitinib
5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine
Clinical Trials
Apoptosis
Cell Line
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Small, Jeffrey ; Washburn, Erik ; Millington, Karmaine ; Zhu, Junjia ; Holder, Sheldon. / The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors. In: Oncotarget. 2017 ; Vol. 8, No. 56. pp. 95116-95134.
@article{fe4e8277c82943cca81ac9de4dc92177,
title = "The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors",
abstract = "Multiple therapies currently exist for renal cell carcinoma, however, most do not result in cure and the development of acquired resistance is the rule rather than the exception. CDK4/6 and PIM1 kinases are potential new therapeutic targets in RCC. Abemaciclib is a potent CDK4/6 and PIM1 kinase inhibitor, thus we evaluated the effects of abemaciclib on renal cell carcinoma. In vitro, abemaciclib causes decreased cellular viability, increased apoptosis, and alterations in autophagy in renal cell carcinoma cell lines. A pre-clinical mouse model of RCC shows abemaciclib in combination with sunitinib to cause dramatic reduction in tumor sizes without overt toxicity. Thus abemaciclib is active in renal cell carcinoma and should be evaluated in a clinical trial in combination with sunitinib. Additionally, CDK4/6 and PIM1 kinase appear to be viable clinical targets in renal cell carcinoma.",
author = "Jeffrey Small and Erik Washburn and Karmaine Millington and Junjia Zhu and Sheldon Holder",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.19618",
language = "English (US)",
volume = "8",
pages = "95116--95134",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "56",

}

The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors. / Small, Jeffrey; Washburn, Erik; Millington, Karmaine; Zhu, Junjia; Holder, Sheldon.

In: Oncotarget, Vol. 8, No. 56, 01.01.2017, p. 95116-95134.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

AU - Small, Jeffrey

AU - Washburn, Erik

AU - Millington, Karmaine

AU - Zhu, Junjia

AU - Holder, Sheldon

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Multiple therapies currently exist for renal cell carcinoma, however, most do not result in cure and the development of acquired resistance is the rule rather than the exception. CDK4/6 and PIM1 kinases are potential new therapeutic targets in RCC. Abemaciclib is a potent CDK4/6 and PIM1 kinase inhibitor, thus we evaluated the effects of abemaciclib on renal cell carcinoma. In vitro, abemaciclib causes decreased cellular viability, increased apoptosis, and alterations in autophagy in renal cell carcinoma cell lines. A pre-clinical mouse model of RCC shows abemaciclib in combination with sunitinib to cause dramatic reduction in tumor sizes without overt toxicity. Thus abemaciclib is active in renal cell carcinoma and should be evaluated in a clinical trial in combination with sunitinib. Additionally, CDK4/6 and PIM1 kinase appear to be viable clinical targets in renal cell carcinoma.

AB - Multiple therapies currently exist for renal cell carcinoma, however, most do not result in cure and the development of acquired resistance is the rule rather than the exception. CDK4/6 and PIM1 kinases are potential new therapeutic targets in RCC. Abemaciclib is a potent CDK4/6 and PIM1 kinase inhibitor, thus we evaluated the effects of abemaciclib on renal cell carcinoma. In vitro, abemaciclib causes decreased cellular viability, increased apoptosis, and alterations in autophagy in renal cell carcinoma cell lines. A pre-clinical mouse model of RCC shows abemaciclib in combination with sunitinib to cause dramatic reduction in tumor sizes without overt toxicity. Thus abemaciclib is active in renal cell carcinoma and should be evaluated in a clinical trial in combination with sunitinib. Additionally, CDK4/6 and PIM1 kinase appear to be viable clinical targets in renal cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85033407468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033407468&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19618

DO - 10.18632/oncotarget.19618

M3 - Article

VL - 8

SP - 95116

EP - 95134

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 56

ER -